Novartis starts building new radioligand therapy site in Denton, Texas, expanding US cancer treatment network.

Novartis has begun construction on a new 46,000 sq. ft radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking a key step in its $23 billion US investment plan. This site will be the fifth RLT manufacturing location in the US, enhancing access to personalized cancer treatments across the southern US and strengthening Novartis' coast-to-coast RLT network. The facility is expected to be operational by 2028 and will create new jobs in bioengineering and manufacturing. This expansion supports Novartis' leadership in delivering advanced cancer therapies and ensures reliable treatment supply closer to patients.